{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T09:14:55Z","timestamp":1778145295882,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xkme.2026.101311","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:15:26Z","timestamp":1772122526000},"page":"101311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["C3 Glomerulonephritis Associated With Anti-complement Factor B Antibodies Following Anti-cancer Treatment With Pembrolizumab"],"prefix":"10.1016","volume":"8","author":[{"given":"Persia","family":"Stroppou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Asaelof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Panayides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Arsali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michalis","family":"Spartalis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Kevrekidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Themis","family":"Christofi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theophanis","family":"Theophanous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantinos","family":"Michaelides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin J.","family":"Marchbank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyproula","family":"Dimitriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4588-4738","authenticated-orcid":false,"given":"Nicos","family":"Mitsides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.xkme.2026.101311_bib1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ki.2012.212","article-title":"C3 glomerulonephritis: Clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up","volume":"82","author":"Sethi","year":"2012","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.xkme.2026.101311_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy \u2014 understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"10.1016\/j.xkme.2026.101311_bib3","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00467-017-3702-8","article-title":"C3 glomerulonephritis with a severe crescentic phenotype","volume":"32","author":"Ravindran","year":"2017","journal-title":"Pediatric Nephrology"},{"key":"10.1016\/j.xkme.2026.101311_bib4","series-title":"GeneReviews\u00ae","article-title":"C3 Glomerulopathy Summary Genetic counseling","author":"Mart\u00edn","year":"1993"},{"issue":"3","key":"10.1016\/j.xkme.2026.101311_bib5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ajmg.c.31986","article-title":"C3 glomerulopathy: Understanding an ultra-rare complement-mediated renal disease","volume":"190","author":"Heiderscheit","year":"2022","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"2","key":"10.1016\/j.xkme.2026.101311_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40620-015-0218-9","article-title":"C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?","volume":"29","author":"Alexander","year":"2016","journal-title":"J Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101311_bib7","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1093\/ibd\/izy070","article-title":"The complexity of renal involvment in IBD - C3 glomerulopathy in ulcerative colitis","volume":"24","author":"Marques Da Costa","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"10.1016\/j.xkme.2026.101311_bib8","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.3390\/ijms24119369","article-title":"Infection-related cryoglobulinemic glomerulonephritis with serum anti-factor B antibodies identified and staining for NAPlr\/Plasmin activity due to infective endocarditis","volume":"24","author":"Toishi","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.xkme.2026.101311_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41581-020-0263-z","article-title":"Bacterial infection linked to anti-factor B antibodies","volume":"16","author":"Wang","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2026.101311_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/ckj\/sfw032","article-title":"Revisiting post-infectious glomerulonephritis in the emerging era of C3 glomerulopathy","volume":"9","author":"Khalighi","year":"2016","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.xkme.2026.101311_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-023-03202-5","article-title":"Pembrolizumab induced-C3 glomerulonephritis and RBC cast nephropathy: a case report","volume":"24","author":"Yang","year":"2023","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.xkme.2026.101311_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2019.11.011","article-title":"C3 glomerulonephritis in a patient treated with anti\u2013PD-1 antibody","volume":"125","author":"Ville","year":"2020","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.xkme.2026.101311_bib13","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1681\/ASN.2005010103","article-title":"Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome","volume":"16","author":"Kavanagh","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2026.101311_bib14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1086\/318203","article-title":"Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition","volume":"68","author":"Richards","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"7","key":"10.1016\/j.xkme.2026.101311_bib15","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.molimm.2005.06.041","article-title":"Does complement factor B have a role in the pathogenesis of atypical HUS?","volume":"43","author":"Kavanagh","year":"2006","journal-title":"Mol Immunol"},{"issue":"13","key":"10.1016\/j.xkme.2026.101311_bib16","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","article-title":"Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome","volume":"112","author":"Fr\u00e9meaux-Bacchi","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.xkme.2026.101311_bib17","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1681\/ASN.2015010100","article-title":"A de novo deletion in the regulators of complement activation cluster producing a hybrid complement factor H\/complement factor H-related 3 gene in atypical hemolytic uremic syndrome","volume":"27","author":"Challis","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.xkme.2026.101311_bib18","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.imbio.2016.05.002","article-title":"Chromosomal rearrangement\u2014A rare cause of complement factor I associated atypical haemolytic uraemic syndrome","volume":"221","author":"Gleeson","year":"2016","journal-title":"Immunobiology"},{"issue":"1","key":"10.1016\/j.xkme.2026.101311_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.imbio.2013.06.004","article-title":"Standardisation of the factor H autoantibody assay","volume":"219","author":"Watson","year":"2014","journal-title":"Immunobiology"},{"issue":"3","key":"10.1016\/j.xkme.2026.101311_bib20","first-page":"417","article-title":"Factor I Autoantibodies in Patients with Atypical Hemolytic Uremic Syndrome: Disease-Associated or an Epiphenomenon?","volume":"7","author":"Kavanagh","year":"2012","journal-title":"Clin j Am Soc"},{"issue":"11","key":"10.1016\/j.xkme.2026.101311_bib21","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2215\/CJN.00320121","article-title":"C3 Glomerulopathy and Related Disorders in Children Etiology-Phenotype Correlation and Outcomes","volume":"16","author":"Wong","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101311_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers15061891","article-title":"Immune checkpoint inhibitors and the kidney: a focus on diagnosis and management for personalised medicine","volume":"15","author":"Longhitano","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.xkme.2026.101311_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100682","article-title":"Pembrolizumab-induced anti-GBM glomerulonephritis: a case report","volume":"5","author":"El Yamani","year":"2023","journal-title":"Kidney Med"},{"issue":"1","key":"10.1016\/j.xkme.2026.101311_bib24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor\u2013associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.xkme.2026.101311_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-023-03058-9","article-title":"Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study","volume":"24","author":"Welte","year":"2023","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101311_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-017-0802-4","article-title":"Treating C3 glomerulopathy with eculizumab","volume":"19","author":"Welte","year":"2018","journal-title":"BMC Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2026.101311_bib27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2011-03-339903","article-title":"A novel hybrid CFH\/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome","volume":"119","author":"Francis","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.xkme.2026.101311_bib28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1681\/ASN.2019050515","article-title":"CFHR Gene variations provide insights in the pathogenesis of the kidney diseases atypical hemolytic uremic syndrome and C3 glomerulopathy","volume":"31","author":"Zipfel","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2026.101311_bib29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1681\/ASN.2019080851","article-title":"Anti-factor B antibodies and acute postinfectious GN in children","volume":"31","author":"Chauvet","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101311_bib30","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1681\/ASN.2016030343","article-title":"Anti-factor B and anti-C3b autoantibodies in C3 glomerulopathy and ig-associated membranoproliferative GN","volume":"28","author":"Marinozzi","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2026.101311_bib31","article-title":"Concomitant nephrotic syndrome and cryoglobulinemia in a case of malignant mesothelioma","volume":"2022","author":"Nagai","year":"2022","journal-title":"Case Rep Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101311_bib32","article-title":"A case of prostate cancer presenting with rash","volume":"11","author":"Albawaliz","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.xkme.2026.101311_bib33","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.924283","article-title":"Pembrolizumab-induced cold agglutinin disease","volume":"21","author":"Atiq","year":"2020","journal-title":"Am J Case Rep"},{"issue":"Supplement 1","key":"10.1016\/j.xkme.2026.101311_bib34","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-113341","article-title":"Immune-mediated hematologic complications of checkpoint inhibitors: a review of the literature","volume":"132","author":"Sallam","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.xkme.2026.101311_bib35","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/annonc\/mdx126","article-title":"Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient","volume":"28","author":"Pellegrino","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.xkme.2026.101311_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2020.04.025","article-title":"Late immune-related adverse events in long-term responders to PD-1\/PD-L1 checkpoint inhibitors: a multicentre study","volume":"134","author":"Nigro","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.xkme.2026.101311_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13256-021-02766-w","article-title":"Atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors: a case report","volume":"15","author":"Kyriazis","year":"2021","journal-title":"J Med Case Rep"},{"issue":"3","key":"10.1016\/j.xkme.2026.101311_bib38","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1681\/ASN.0000000526","article-title":"Safety and efficacy of avacopan in patients with complement 3 glomerulopathy: randomized, double-blind clinical trial","volume":"36","author":"Bomback","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101311_bib39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ekir.2024.09.030","article-title":"Efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent complement 3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis","volume":"10","author":"Bomback","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"12","key":"10.1016\/j.xkme.2026.101311_bib40","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy","volume":"8","author":"Wong","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"10S","key":"10.1016\/j.xkme.2026.101311_bib41","volume":"35","author":"Nester","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"10512","key":"10.1016\/j.xkme.2026.101311_bib42","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(25)01148-1","article-title":"Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study","volume":"406","author":"Kavanagh","year":"2025","journal-title":"Lancet"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526000725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526000725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:39:47Z","timestamp":1778143187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526000725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2590059526000725"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101311","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"C3 Glomerulonephritis Associated With Anti-complement Factor B Antibodies Following Anti-cancer Treatment With Pembrolizumab","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101311"}}